App improves episodic memory by 40%.
Investors concerned over strong placebo effect
Patients to get Santhera’s Raxone under EAMS scheme.
Mydadis approval ends decade-long saga with FDA.
Erenumab could be first new treatment in a decade.
Formerly known as MRC Technology, charity to spend Keytruda royalties on R&D considered too risky by big pharma
Blockbuster hopeful could launch next year if approved.
AZ says migraine outside its strategic focus.